admin – Page 7064 – Get News Story

HER2 Negative Breast Cancer Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisa

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, HER2 Negative Breast Cancer pipeline constitutes 85+ key companies continuously working towards developing 85+ HER2 Negative Breast Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The HER2 Negative Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“HER2 Negative Breast Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HER2 Negative Breast Cancer Market.

Some of the key takeaways from the HER2 Negative Breast Cancer Pipeline Report:

Companies across the globe are diligently working toward developing novel HER2 Negative Breast Cancer treatment therapies with a considerable amount of success over the years.
HER2 Negative Breast Cancer companies working in the treatment market are EnhancedBio Inc, Relay Therapeutics, Inc., Prelude Therapeutics, Ellipses Pharma, Beta Pharma, CytomX Therapeutics, Atossa Therapeutics, Inc, AstraZeneca, Roche, Celcuity, Inc., BeiGene, Olema Pharmaceuticals, Inc., AstraZeneca, Adagene Inc, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Genentech, and others, are developing therapies for the HER2 Negative Breast Cancer treatment

Emerging HER2 Negative Breast Cancer therapies in the different phases of clinical trials are- ER-PROTAC, RLY-2608, PRT2527, EP0062, BPI-1178, CX-2009, Z-endoxifen, AZD9833, GDC-9545, Gedatolisib, BGB-290, OP-1250, AZD9833, ADG106, Dato-DXd, HRS8807, Ipatasertib, and others are expected to have a significant impact on the HER2 Negative Breast Cancer market in the coming years.
In January 2023, Context Therapeutics Inc., a company dedicated to developing innovative therapies for solid tumors, particularly focusing on female-related cancers, announced that its clinical trial collaborator, Stemline Therapeutics, Inc., a wholly owned subsidiary of The Menarini Group (“Menarini”), has obtained FDA approval for ORSERDU (elacestrant). This approval is specifically for the treatment of postmenopausal women or adult men diagnosed with estrogen receptor–positive (ER+), HER2-negative (HER2-), Estrogen Receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer. This approval is granted for individuals whose disease has progressed despite undergoing at least one line of endocrine therapy.
On January 27, 2023, The FDA has granted approval for elacestrant (Orserdu) to treat advanced or metastatic breast cancer in postmenopausal women or adult men. Specifically, this approval is for cases where the cancer is estrogen receptor-positive (ER+), HER2-negative, and involves mutations in the Estrogen Receptor 1 gene (ESR1). The approval is for individuals whose cancer has progressed despite undergoing at least one line of endocrine therapy.
In January 2023, Daiichi Sankyo and AstraZeneca’s ENHERTU® (trastuzumab deruxtecan) obtained approval in the European Union (EU) as a standalone treatment for adult patients diagnosed with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer. This approval is designated for individuals who have previously undergone chemotherapy in the metastatic stage or experienced disease recurrence while undergoing or within six months after completing adjuvant chemotherapy.
In January 2023, Gilead Sciences, Inc. revealed that the European Medicines Agency (EMA) has validated a Type II variation Marketing Authorization Application (MAA) for Trodelvy (sacituzumab govitecan-hziy) intended for treating adult patients diagnosed with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer. This application is for individuals who have previously undergone endocrine-based therapy and received at least two additional systemic therapies in the metastatic stage.

HER2 Negative Breast Cancer Overview

HER2-negative breast cancer refers to a type of breast cancer where tumor cells do not overexpress a protein called human epidermal growth factor receptor 2 (HER2). HER2 is a protein that plays a role in the growth and division of cells.

Get a Free Sample PDF Report to know more about HER2 Negative Breast Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/her2-negative-breast-cancer-pipeline-insight

Emerging HER2 Negative Breast Cancer Drugs Under Different Phases of Clinical Development Include:

ER-PROTAC: EnhancedBio Inc
RLY-2608: Relay Therapeutics, Inc.
PRT2527: Prelude Therapeutics
EP0062: Ellipses Pharma
BPI-1178: Beta Pharma
CX-2009: CytomX Therapeutics
Z-endoxifen: Atossa Therapeutics, Inc
AZD9833: AstraZeneca
GDC-9545: Roche
Gedatolisib: Celcuity, Inc.
BGB-290: BeiGene
OP-1250: Olema Pharmaceuticals, Inc.
AZD9833: AstraZeneca
ADG106: Adagene Inc
Dato-DXd: Daiichi Sankyo, Inc.
HRS8807: Shanghai Hengrui Pharmaceutical Co., Ltd.
Ipatasertib: Genentech

HER2 Negative Breast Cancer Route of Administration

HER2 Negative Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

HER2 Negative Breast Cancer Molecule Type

HER2 Negative Breast Cancer Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

HER2 Negative Breast Cancer Pipeline Therapeutics Assessment

HER2 Negative Breast Cancer Assessment by Product Type
HER2 Negative Breast Cancer By Stage and Product Type
HER2 Negative Breast Cancer Assessment by Route of Administration
HER2 Negative Breast Cancer By Stage and Route of Administration
HER2 Negative Breast Cancer Assessment by Molecule Type
HER2 Negative Breast Cancer by Stage and Molecule Type

DelveInsight’s HER2 Negative Breast Cancer Report covers around 85+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further HER2 Negative Breast Cancer product details are provided in the report. Download the HER2 Negative Breast Cancer pipeline report to learn more about the emerging HER2 Negative Breast Cancer therapies

Some of the key companies in the HER2 Negative Breast Cancer Therapeutics Market include:

Key companies developing therapies for HER2 Negative Breast Cancer are – Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai Co., Ltd., BeiGene, Olema Pharmaceuticals, AstraZeneca, Radius Health, Shanghai Hengrui Pharmaceutical Co., Ltd., OncoSec Medical Incorporated, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pfizer, Adagene Inc, H3 Biomedicine Inc., Daiichi Sankyo, Inc., InventisBio Co., Ltd, Context Therapeutics, Boehringer Ingelheim, CytomX Therapeutics, Beta Pharma (Suzhou) Co., Ltd., Eli Lilly and Company, Laekna Limited, Sermonix Pharmaceuticals Inc., and others.

HER2 Negative Breast Cancer Pipeline Analysis:

The HER2 Negative Breast Cancer pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of HER2 Negative Breast Cancer with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2 Negative Breast Cancer Treatment.
HER2 Negative Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
HER2 Negative Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2 Negative Breast Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about HER2 Negative Breast Cancer drugs and therapies

HER2 Negative Breast Cancer Pipeline Market Drivers

HER2 protein is considered a relevant biomarker for treatment, growing prevalence of Breast Cancer are some of the important factors that are fueling the HER2 Negative Breast Cancer Market.

HER2 Negative Breast Cancer Pipeline Market Barriers

However, poor understanding in the context of breast cancer subtype, lack of research in identification of factors involved in resistance and other factors are creating obstacles in the HER2 Negative Breast Cancer Market growth.

Scope of HER2 Negative Breast Cancer Pipeline Drug Insight

Coverage: Global
Key HER2 Negative Breast Cancer Companies: EnhancedBio Inc, Relay Therapeutics, Inc., Prelude Therapeutics, Ellipses Pharma, Beta Pharma, CytomX Therapeutics, Atossa Therapeutics, Inc, AstraZeneca, Roche, Celcuity, Inc., BeiGene, Olema Pharmaceuticals, Inc., AstraZeneca, Adagene Inc, Daiichi Sankyo, Inc., Shanghai Hengrui Pharmaceutical Co., Ltd., Genentech, and others
Key HER2 Negative Breast Cancer Therapies: ER-PROTAC, RLY-2608, PRT2527, EP0062, BPI-1178, CX-2009, Z-endoxifen, AZD9833, GDC-9545, Gedatolisib, BGB-290, OP-1250, AZD9833, ADG106, Dato-DXd, HRS8807, Ipatasertib, and others
HER2 Negative Breast Cancer Therapeutic Assessment: HER2 Negative Breast Cancer current marketed and HER2 Negative Breast Cancer emerging therapies
HER2 Negative Breast Cancer Market Dynamics: HER2 Negative Breast Cancer market drivers and HER2 Negative Breast Cancer market barriers

Request for Sample PDF Report for HER2 Negative Breast Cancer Pipeline Assessment and clinical trials

Table of Contents

1. HER2 Negative Breast Cancer Report Introduction

2. HER2 Negative Breast Cancer Executive Summary

3. HER2 Negative Breast Cancer Overview

4. HER2 Negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment

5. HER2 Negative Breast Cancer Pipeline Therapeutics

6. HER2 Negative Breast Cancer Late Stage Products (Phase II/III)

7. HER2 Negative Breast Cancer Mid Stage Products (Phase II)

8. HER2 Negative Breast Cancer Early Stage Products (Phase I)

9. HER2 Negative Breast Cancer Preclinical Stage Products

10. HER2 Negative Breast Cancer Therapeutics Assessment

11. HER2 Negative Breast Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. HER2 Negative Breast Cancer Key Companies

14. HER2 Negative Breast Cancer Key Products

15. HER2 Negative Breast Cancer Unmet Needs

16 . HER2 Negative Breast Cancer Market Drivers and Barriers

17. HER2 Negative Breast Cancer Future Perspectives and Conclusion

18. HER2 Negative Breast Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: HER2 Negative Breast Cancer Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisa

Gaucher’s disease Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AvroBio, Orphazyme, Eli Lilly and Company, Sanofi

Gaucher’s disease pipeline constitutes 14+ key companies continuously working towards developing 16+ Gaucher’s disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Gaucher’s disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Gaucher’s disease Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gaucher’s disease Market.

Some of the key takeaways from the Gaucher’s disease Pipeline Report:

Companies across the globe are diligently working toward developing novel Gaucher’s disease treatment therapies with a considerable amount of success over the years. Gaucher’s disease Key players such as – Gain therapeutics, M6P Therapeutics, AvroBio, Orphazyme, Eli Lilly and Company, Sanofi, and others,are developing therapies for the Gaucher’s disease treatment

Gaucher’s disease Emerging therapies such as – GBA programme, M 011, AVR-RD-02, Arimoclomol, GBA1 Gene Therapy, Venglustat, and others are expected to have a significant impact on the Gaucher’s disease market in the coming years.
In April 2022, Sanofi initiated a parallel arm, Phase 3, double-blind, double-dummy,active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezymeinfusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and adult patients with Gaucher disease Type 3 (GD3) who have been treated with Enzyme Replacement Therapy (ERT) for at least 3 years

Gaucher’s disease Overview

Gaucher disease is a rare, inherited metabolic disorder in which deficiency of the enzyme glucocerebrosidase results in the accumulation of harmful quantities of certain fats (lipids), specifically the glycolipid glucocerebroside, throughout the body especially within the bone marrow, spleen and liver. The symptoms and physical findings associated with Gaucher disease vary greatly from patient to patient.

Get a Free Sample PDF Report to know more about Gaucher’s disease Pipeline Assessment-

https://www.delveinsight.com/report-store/gauchers-disease-pipeline-insight

Gaucher’s disease Pipeline Therapeutics Assessment

Gaucher’s disease Assessment by Product Type
Gaucher’s disease By Stage and Product Type
Gaucher’s disease Assessment by Route of Administration
Gaucher’s disease By Stage and Route of Administration
Gaucher’s disease Assessment by Molecule Type
Gaucher’s disease by Stage and Molecule Type

DelveInsight’s Gaucher’s disease Report covers around 16+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Emerging Gaucher’s disease Drugs Under Different Phases of Clinical Development Include:

GBA programme: Gain therapeutics
M 011: M6P Therapeutics
AVR-RD-02: AvroBio
Arimoclomol: Orphazyme
GBA1 Gene Therapy: Eli Lilly and Company
Venglustat: Sanofi

Gaucher’s disease Pipeline Analysis:

The Gaucher’s disease pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the Gaucher’s disease treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gaucher’s disease Treatment.
Gaucher’s disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Gaucher’s disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gaucher’s disease market.

Further Gaucher’s disease product details are provided in the report. Download the Gaucher’s disease pipeline report to learn more about the emerging Gaucher’s disease therapies

Gaucher’s disease Pipeline Market Drivers

Increasing investment for healthcare infrastructure
Rising prevalence of lysosomal disease

Gaucher’s disease Pipeline Market Barriers

High cost associated with the treatment
Lack of awareness among people in developing countries

Scope of Gaucher’s disease Pipeline Drug Insight

Coverage: Global
Key Gaucher’s disease Companies: Gain therapeutics, M6P Therapeutics, AvroBio, Orphazyme, Eli Lilly and Company, Sanofi, and others
Key Gaucher’s disease Therapies: GBA programme, M 011, AVR-RD-02, Arimoclomol, GBA1 Gene Therapy, Venglustat, and others
Gaucher’s disease Therapeutic Assessment: Gaucher’s disease current marketed and Gaucher’s disease emerging therapies
Gaucher’s disease Market Dynamics: Gaucher’s disease market drivers and Gaucher’s disease market barriers

Request for Sample PDF Report for Gaucher’s disease Pipeline Assessment and clinical trials

Table of Contents

1	Gaucher’s disease Report Introduction
2	Gaucher’s disease Executive Summary
3	Gaucher’s disease Overview
4	Gaucher’s disease- Analytical Perspective In-depth Commercial Assessment
5	Gaucher’s disease Pipeline Therapeutics
6	Gaucher’s disease Late Stage Products (Phase II/III)
7	Gaucher’s disease Mid Stage Products (Phase II)
8	Gaucher’s disease Early Stage Products (Phase I)
9	Gaucher’s disease Preclinical Stage Products
10	Gaucher’s disease Therapeutics Assessment
11	Gaucher’s disease Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Gaucher’s disease Key Companies
14	Gaucher’s disease Key Products
15	Gaucher’s disease Unmet Needs
16	Gaucher’s disease Market Drivers and Barriers
17	Gaucher’s disease Future Perspectives and Conclusion
18	Gaucher’s disease Analyst Views
19	Appendix
20	About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gaucher’s disease Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | AvroBio, Orphazyme, Eli Lilly and Company, Sanofi

Experience the Unbridled & Inspiring Energy of Love – Shane Josephson & Burnt Earth Band Present “Show The Love”

From the heart of Cobar, a one of its kind Bush Metal anthem exhilarates audiences, rejuvenating their soul and igniting joy

”Show The Love,” the latest single from Shane Josephson featuring the Burnt Earth Band, is more than just a song; it’s a call to action—a musical manifesto that invites listeners to let go of their stresses and immerse themselves in the sheer joy of music.

Released on March 1st, this track stands out as a pinnacle of bush metal, a genre that encapsulates the rugged beauty and spirit of the Australian bushland with the hard-hitting vibes of rock music. This new single builds on the success of past hits like “Eureka (The Solution)” and “A Nation Was Born,” further establishing Shane Josephson and his band as icons in the rock and bush metal genres.

“Show The Love” is designed to be an anthem for those seeking a momentary escape from life’s pressures. It encourages listeners to recharge, clear their minds, and connect with the music on a profound level. The song emphasizes the importance of joy, dancing, singing, and, most importantly, sharing love.

The track stands as a testament to the power of authentic music, created with real instruments by talented musicians. It captures the essence of bush metal—a genre that Shane Josephson and Burnt Earth Band have pioneered, blending the heart of the Australian landscape with the energy of rock music to create something truly unique.

In “Show The Love,” Shane Josephson and the Burnt Earth Band have crafted a timeless song that not only showcases their musical prowess but also offers a beacon of positivity and connection in a world that sorely needs it. The powerful new release is sure to be a hit among fans of all ages, calling everyone to the dance floor of life to jump to the beat of bush metal and embrace the joy of music.

Stream and Download the new single by visiting the artist’s official webpage or YouTube to fully engage with “Show The Love!”

Through this single, Shane Josephson and the Burnt Earth Band invite everyone to become part of a larger community of music lovers who appreciate the power of music to uplift, energize, and inspire!

ABOUT

Hailing from Cobar, New South Wales, Australia, Shane Josephson, in collaboration with the Burnt Earth Band, introduces a fresh and electrifying sound to the rock scene with their distinctive bush metal genre. With the release of their new single, “Show The Love,” on March 1st, 2024, they continue to push the boundaries of music, blending raw energy with a message of liberation and joy.

Two disruptive forces, both Shane Josephson and Burnt Earth Band have carved a niche for themselves by creating music that’s not just heard but experienced, drawing fans into a world where music serves as a powerful escape from the mundane.

LINKS

Spotify: https://open.spotify.com/artist/4mEz0w5DXQunXXkOsGYsQY

Media Contact
Company Name: Shane Josephson-feat: Burnt earth band
Contact Person: Shane Josephson
Email: Send Email
Phone: 0429362047
Address:12 echidna st
City: Cobar
State: NSW
Country: Australia
Website: https://open.spotify.com/artist/4mEz0w5DXQunXXkOsGYsQY

Spinal Cord Injury Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Spinal Cord Injury pipeline constitutes 35+ key companies continuously working towards developing 35+ Spinal Cord Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Spinal Cord Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Spinal Cord Injury Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Cord Injury Market.

Some of the key takeaways from the Spinal Cord Injury Pipeline Report:

Companies across the globe are diligently working toward developing novel Spinal Cord Injury treatment therapies with a considerable amount of success over the years.
Spinal Cord Injury companies working in the treatment market are Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, StemCyte, Inc., and others, are developing therapies for the Spinal Cord Injury treatment

Emerging Spinal Cord Injury therapies in the different phases of clinical trials are- Allogeneic stem cell therapy, OLT1177, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, and others are expected to have a significant impact on the Spinal Cord Injury market in the coming years.
In July 2023, NeuroSolv Therapeutics is in the process of advancing a therapy for spinal cord injuries and is actively seeking investment for clinical trials. The treatment is presently in the clinical trial phase, and should it receive regulatory approval, Perineline™ has the potential to benefit approximately two million individuals worldwide who are grappling with spinal cord injuries. Information provided by the World Health Organization reveals that on a global scale, between 250,000 and 500,000 individuals experience spinal cord injuries annually. In the United Kingdom alone, the Spinal Injury Association reports that there are 50,000 people enduring life-altering spinal cord injuries.

Spinal Cord Injury Overview

A spinal cord injury (SCI) refers to damage to the spinal cord, which is a crucial part of the central nervous system responsible for transmitting messages between the brain and the rest of the body. These injuries often result in a loss of function, including mobility and sensation, below the level of the injury.

Get a Free Sample PDF Report to know more about Spinal Cord Injury Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/spinal-cord-injury-pipeline-insight

Emerging Spinal Cord Injury Drugs Under Different Phases of Clinical Development Include:

Allogeneic stem cell therapy: Athersys
OLT1177: Olatec Therapeutics
ALMB0166: AlaMab therapeutics
AXER-204: ReNetX Bio
FAB117-HC: Histocell
AST-OPC1: Lineage Cell Therapeutics
Elezanumab: AbbVie
MT 3921: Mitsubishi Tanabe Pharma
PMZ-1620: Pharmazz
ES 135: Eusol Biotech
KP-100IT: Kringle Pharma
NVG-291: NervGen Pharma
Romosozumab: VA Office of Research and Development/Kessler Institute for Rehabilitation
Umbilical Cord Blood Mononuclear Cell: StemCyte, Inc

Spinal Cord Injury Route of Administration

Spinal Cord Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Spinal Cord Injury Molecule Type

Spinal Cord Injury Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Spinal Cord Injury Pipeline Therapeutics Assessment

Spinal Cord Injury Assessment by Product Type
Spinal Cord Injury By Stage and Product Type
Spinal Cord Injury Assessment by Route of Administration
Spinal Cord Injury By Stage and Route of Administration
Spinal Cord Injury Assessment by Molecule Type
Spinal Cord Injury by Stage and Molecule Type

DelveInsight’s Spinal Cord Injury Report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Spinal Cord Injury product details are provided in the report. Download the Spinal Cord Injury pipeline report to learn more about the emerging Spinal Cord Injury therapies

Some of the key companies in the Spinal Cord Injury Therapeutics Market include:

Key companies developing therapies for Spinal Cord Injury are – NervGen Pharma, VA Office of Research and Development, Kessler Institute for Rehabilitation, StemCyte, Inc., Mitsubishi Tanabe Pharma America Inc., AbbVie, and others.

Spinal Cord Injury Pipeline Analysis:

The Spinal Cord Injury pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Cord Injury with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Cord Injury Treatment.
Spinal Cord Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Spinal Cord Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Cord Injury market.

Download Sample PDF Report to know more about Spinal Cord Injury drugs and therapies

Spinal Cord Injury Pipeline Market Drivers

Increase in prevalence of spinal cord injury, increasing awareness about the spinal cord injury are some of the important factors that are fueling the Spinal Cord Injury Market.

Spinal Cord Injury Pipeline Market Barriers

However, absence of essential emergency and acute care, lack of importance of a systematic approach towards the management of Spinal cord Injury and other factors are creating obstacles in the Spinal Cord Injury Market growth.

Scope of Spinal Cord Injury Pipeline Drug Insight

Coverage: Global
Key Spinal Cord Injury Companies: Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, NervGen Pharma, StemCyte, Inc., and others
Key Spinal Cord Injury Therapies: Allogeneic stem cell therapy, OLT1177, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, MT 3921, PMZ-1620, ES 135, KP-100IT, NVG-291, Romosozumab, Umbilical Cord Blood Mononuclear Cell, and others
Spinal Cord Injury Therapeutic Assessment: Spinal Cord Injury current marketed and Spinal Cord Injury emerging therapies
Spinal Cord Injury Market Dynamics: Spinal Cord Injury market drivers and Spinal Cord Injury market barriers

Request for Sample PDF Report for Spinal Cord Injury Pipeline Assessment and clinical trials

Table of Contents

1. Spinal Cord Injury Report Introduction

2. Spinal Cord Injury Executive Summary

3. Spinal Cord Injury Overview

4. Spinal Cord Injury- Analytical Perspective In-depth Commercial Assessment

5. Spinal Cord Injury Pipeline Therapeutics

6. Spinal Cord Injury Late Stage Products (Phase II/III)

7. Spinal Cord Injury Mid Stage Products (Phase II)

8. Spinal Cord Injury Early Stage Products (Phase I)

9. Spinal Cord Injury Preclinical Stage Products

10. Spinal Cord Injury Therapeutics Assessment

11. Spinal Cord Injury Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Spinal Cord Injury Key Companies

14. Spinal Cord Injury Key Products

15. Spinal Cord Injury Unmet Needs

16 . Spinal Cord Injury Market Drivers and Barriers

17. Spinal Cord Injury Future Perspectives and Conclusion

18. Spinal Cord Injury Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Spinal Cord Injury Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Athersys, Olatec Therapeutics, AlaMab therapeutics, ReNetX Bio

Monkey Rock Group Inc. (OTC: MKRO) Stock on Radar This Month

Investors often seek hidden opportunities, requiring extensive research to discover them. This underexplored/undervalued company is Monkey Rock Group Inc. (OTC: MKRO), a company based in Italy within the European Union. It operates in the overnight shipping sector, competing with industry giants like FedEx Corporation (NYSE: FDX), United Parcel Service (NYSE: UPS), and (DHL Group) Deutsche Post (OTC: DHLGY).

Monkey Rock Group is active in warehouse handling, temporary work management, freight forwarding, and overland transportation. Since September of last year, it has served as an international operating subsidiary of GE Holding SRL.

GE Holding acquired controlling shares in Monkey Rock on August 8, 2023. Subsequently, GE Holding implemented a new board of directors, a seasoned management team, and engaged a PCOAB accounting firm to equip the company for a competitive edge in the global transportation sector.

After the transaction, Monkey Rock’s workforce expanded to over 1900 employees, overseeing 70 plants. Notably, the company achieved annual consolidated revenues amounting to $285 million.

Recently, it came to light that the company is in the process of finalizing its annual report, set to be completed before the March 31, 2024, filing deadline. Monkey Rock’s strategic objectives for the 2024 are not only focused on continuous improvements but also on strategic acquisitions aimed at fostering growth. Furthermore, the new management intends to decrease the number of issued common stock shares from the previous administration.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Monkey Rock Group Inc. (OTC: MKRO) Stock on Radar This Month

Carmel-by-the-Sea, CA, Realtor Agents Leverage Lifelong Peninsula Knowledge for Client Success Since 2016

Since entering the real estate scene in 2016, Alex Brant has quickly distinguished himself as a leading figure in Carmel-by-the-Sea, CA. His approach to real estate is deeply influenced by his lifelong connection to the Monterey Peninsula, providing him with unparalleled insights that benefit his clients. This unique perspective has been key to his success, helping him leverage his knowledge for the advantage of those looking to buy or sell in this beautiful coastal area.

“Understanding the nuances of this market is crucial,” says Brant. “My background and upbringing here allow me to offer my clients more than just real estate advice. It’s about sharing a piece of what makes life here so special.”

Brant’s expertise and dedication have made him a standout among Realtors in Carmel-by-the-Sea, CA. His commitment to excellence and his ability to connect with clients on a personal level have not only driven his success but also enriched the experiences of those he works with. As a real estate agent in Carmel-by-the-Sea, CA, Brant has built a reputation for being not just a realtor but a trusted advisor and friend to his clients.

The local knowledge Brant possesses is a critical asset, especially for those new to the area or looking to find that perfect piece of the Monterey Peninsula to call home. His role as one of the premier agents, is reinforced by his track record of successful transactions and satisfied clients.

For those considering a move to the Monterey Peninsula or looking to sell their property, Brant’s record speaks for itself. As a real estate selling agent in Carmel-by-the-Sea, CA, he brings unparalleled expertise and a personal commitment to each client’s success. “My goal is to make the buying or selling process as seamless and enjoyable as possible,” says Brant. “I’m here to help you navigate the market with confidence.”

To learn more about Alex Brant and his services, visit http://alexbrant.com/. Whether you’re buying or selling, Brant’s expertise and passion for the Monterey Peninsula make him the ideal partner in your real estate journey.

Media Contact
Company Name: Alex Brant | Compass Real Estate Agent in Carmel-by-the-Sea CA
Contact Person: Media Relations
Email: Send Email
Phone: +1 831-264-3870
Address:6th Avenue 2SW of, San Carlos St
City: Carmel-by-the-Sea
State: California 93921
Country: United States
Website: http://alexbrant.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Carmel-by-the-Sea, CA, Realtor Agents Leverage Lifelong Peninsula Knowledge for Client Success Since 2016

Raleigh, NC Celebrates Jami Amidon’s Recognition as Top REALTORⓇ in Raleigh, NC, with Multiple Awards

Raleigh, NC – The Raleigh real estate community is abuzz with the news of Jami Amidon’s latest awards, marking her as a top REALTORⓇ in Raleigh, NC. Amidon, known for her dedication and passion for connecting people with their ideal homes, has been honored with several prestigious awards, underscoring her impact in the Raleigh, NC, and surrounding areas.

Receiving the 7 STAR Recipient BRAG Award and the 2022 Top Agent Award has positioned her as a leading real estate agent in Raleigh, NC. This is complemented by her ranking as one of the Top 10 Agents at KW Raleigh in 2022 and her notable performance in the Triangle MLS, where she ranked in the top 1% in units sold. Her team’s achievement as the Top Producing Team in KW Raleigh – GCI further cements her status as one of the top agents in the area.

Amidon’s journey in real estate is backed by a robust foundation of experience, including a successful stint as a Mortgage Branch Manager where she was ranked #2 in the nation. Her insights into the real estate market are sought after, making her a respected National Podcast Guest Speaker. Moreover, Amidon’s commitment to excellence is reflected in her being professionally coached by Tom Ferry International, the #1 leading real estate coach in the United States.

Best real estate agents in Raleigh, NC, like Amidon, are setting new standards in the industry, demonstrating that real estate is not just about transactions but about making a positive difference in people’s lives. “Real estate, to me, is about unlocking possibilities and guiding people to spaces that add joy to their lives,” Amidon shares. Her approach to real estate is holistic, focusing on not just the sale but on ensuring clients find their perfect place in the world.

For those looking to buy or sell their home in Raleigh, Jami Amidon offers a blend of award-winning service, market expertise, and a personalized touch. Visit https://www.jamiamidon.com to discover how Amidon and her team can assist you in navigating the Raleigh real estate market.

“Join us in celebrating this journey and let us help you find your special spot in the world,” Amidon invites potential clients, reinforcing her commitment to exceptional real estate service in Raleigh, NC.

Media Contact
Company Name: Jami Amidon | Real Estate Agent in Raleigh NC | KWRaleigh
Contact Person: Jami Amidon
Email: Send Email
Phone: +1 919-444-2455
City: Raleigh
State: North Carolina
Country: United States
Website: https://www.jamiamidon.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Raleigh, NC Celebrates Jami Amidon\’s Recognition as Top REALTORⓇ in Raleigh, NC, with Multiple Awards

Realtors in Boca Raton FL: Delivering Consistent Success with Proven Marketing and Negotiation Techniques

The Boca Raton, Florida, real estate market is a realm where only the most effective marketing and negotiation strategies lead to success. Matan Morag, P.A., at Regency Realty Services, exemplifies this principle, consistently delivering outstanding results for his clients through proven techniques and an innovative approach to the real estate process.

In a market as sophisticated and competitive as Boca Raton’s, the importance of effective marketing and strong negotiation skills cannot be overstated. Matan Morag’s firm grasp of these crucial aspects has cemented his reputation as a provider of unparalleled service in the Boca Raton real estate community.

Leveraging years of industry experience and advanced marketing tactics, Matan has established himself as a leading real estate agent in Boca Raton, FL. His strategic use of omnipresent marketing and advertising principles ensures that each property is showcased to its fullest potential, attracting the right buyers and securing the best possible terms.

Effective negotiation is an art that Matan, as a top Realtor agent in Boca Raton, FL, has mastered. His clients benefit from his ability to navigate complex deals, ensuring their interests are represented robustly at the negotiation table. This skill set is particularly advantageous in the current climate of high interest rates and limited inventory, where every advantage counts.

The combination of Matan’s marketing acumen and negotiation expertise as a real estate selling agent Boca Raton, FL, has repeatedly proven to be a formula for success. Clients looking to sell their properties find that his techniques lead to swift and profitable transactions, while buyers are guided to make wise investments that align with their long-term goals.

Recognizing the need for a tailored approach in the diverse Boca Raton market, Matan and his team have dedicated themselves to becoming the Realtors Boca Raton FL clients trust most. Their commitment to excellence and client satisfaction is unwavering, and they continue to adapt and thrive, even as market conditions evolve.

The agency is open seven days a week and are always available to help customers find or sell a home. The website offers a variety of properties, resources, and contact information. Visit www.matanmoragpa.com for details.

Media Contact
Company Name: Matan Morag, P.A. At Regency Realty Services | Real Estate Agent in Boca Raton FL
Contact Person: Matan Morag
Email: Send Email
Phone: +1 561-706-0095
Address:861 Yamato Road Ste 5
City: Boca Raton
State: Florida 33431
Country: United States
Website: https://matanmoragpa.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Realtors in Boca Raton FL: Delivering Consistent Success with Proven Marketing and Negotiation Techniques

St. Augustine, FL Realtor Emphasizes Importance of Experience for Successful Home Sales

In the historic and vibrant real estate market of St. Augustine, FL, experience and trustworthiness stand out as pivotal qualities for any real estate agent. Andrew Butler, a seasoned Realtor in St. Augustine, FL, brings these invaluable traits to the forefront, offering his clients unparalleled service backed by years of successful home sales. Since beginning his career, Butler has demonstrated a profound understanding of what it takes to navigate the complexities of the local market, ensuring his clients achieve their real estate goals with confidence and ease.

“Choosing a real estate agent with a proven track record is essential,” Butler advises. “It’s the depth of experience that enables an agent to identify and articulate what buyers and sellers need to consider for a successful transaction.” This level of insight is what has established Butler as a leading real estate selling agent in St. Augustine, FL, trusted by clients for his honesty, integrity, and deep market knowledge.

Butler’s approach to real estate is comprehensive, focusing not just on the aesthetics of a property but also on the essential, often overlooked mechanical aspects. “From the condition of the HVAC system to the age of the roof, understanding the full picture of a property’s condition is crucial,” he notes. This attention to detail ensures his clients are informed and prepared, avoiding potential hidden costs down the line.

Furthermore, Butler provides clients with essential tips for preparing their homes for the market, from decluttering countertops to enhancing curb appeal. These strategies are part of his commitment to offering a personalized service that addresses all aspects of the selling process. “My goal is to make each client feel like they are my only client, providing a tailored service that meets their unique needs,” Butler says.

For those seeking an experienced and dedicated real estate agent in St. Augustine, FL, Andrew Butler offers the expertise and personalized attention needed to navigate the market successfully. Visit https://noahbaileygroup.com/team/andrew-butler to learn more about how Butler’s experience and client-focused approach can lead to your success in St. Augustine’s dynamic real estate landscape.

Media Contact
Company Name: Andrew Butler – Real Estate Agent in St. Augustine, Fl
Contact Person: Andrew Butler
Email: Send Email
Phone: +1 904-844-0122
Address:403 Anastasia Blvd.
City: St. Augustine
State: Florida 32080
Country: United States
Website: https://noahbaileygroup.com/team/andrew-butler

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: St. Augustine, FL Realtor Emphasizes Importance of Experience for Successful Home Sales

Top Goodyear, AZ, Realtors: Waiting Buyers Risk Missing Out on Current Market Advantages

Goodyear, AZ – In the ever-evolving landscape of the Goodyear real estate market, Matt & Shalin Caren, well-known real estate agents in Goodyear, AZ, are advising potential buyers on the risks of waiting for market conditions to change. With interest rates fluctuating and market dynamics shifting, the Caren’s offer crucial insights into why now might be the best time to make a move.

The Caren’s highlight that despite the higher interest rates and stable prices, the current market presents unique advantages. “With fewer buyers actively searching, those who choose to enter the market now find themselves in a less competitive environment,” Matt & Shalin Caren explain. This scenario, uncommon in recent years, allows for better negotiations and potentially more favorable terms for buyers ready to make their home purchase now.

As the leading Realtors in Goodyear, AZ, the Caren’s have observed firsthand the pitfalls of waiting for the “perfect” market conditions. “Waiting on the sidelines might seem safe, but it leads to a scenario where buyers re-enter the market all at once, driving prices up and making for fierce competition”, they caution. This aspect is especially important, considering the recent history of buyers offering well above asking prices and forgoing seller concessions to secure a home.

The Caren Team’s message to potential buyers is clear: the current market conditions, while not without their challenges, offer opportunities that might not be available once more buyers decide to return. “This isn’t just about navigating the market; it’s about seizing opportunities that might not come around again soon,” the Caren’s add.

For those contemplating the timing of their home purchase, Matt & Shalin Caren, real estate selling agents in Goodyear, AZ, stand ready to provide expert guidance and support. Buyers and sellers are encouraged to visit https://www.thecarenteam.com/ to explore how the Caren Team can assist in making informed decisions in today’s market.

The Caren Team suggests for those in the market looking to buy or sell to download and install their app from https://CarenTeamApp.com which provides valuable insights to buyers and sellers.

“Let us help you understand the current market better and guide you through making a decision that aligns with your long-term goals,” invite the Caren’s, underscoring their commitment to assisting buyers in Goodyear, AZ.

Media Contact
Company Name: The Caren Team
Contact Person: Matt Caren
Email: Send Email
Phone: +1 602-777-6683
Address:2950 N Litchfield Road, Suite 111
City: Goodyear
State: Arizona 85395
Country: United States
Website: https://www.thecarenteam.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Top Goodyear, AZ, Realtors: Waiting Buyers Risk Missing Out on Current Market Advantages